FDA Clearance Tracker · P080012-S021
PROMETRA PROGRAMMABLE INFUSION PUMP SYSTEM
Last checked: Nov 20, 2026Latest source record: Feb 10, 2015 (this decision)Source: openFDAMethods & limitations
Decided
Feb 10, 2015
Approved
Time to decision
288 days
Received Apr 28, 2014. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P080012-S021
- Device name
- PROMETRA PROGRAMMABLE INFUSION PUMP SYSTEM
- Applicant
- Infusyn Therapeutics, LLC
- Applicant location
- Hackettstown, NJ
- Received
- Apr 28, 2014
- Decided
- Feb 10, 2015
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P080012
Device type
- Device class
- Class III
- Specialty
- Hospital Medicine & Nursing
FDA's approval statement
As written in FDA's record.
APPROVAL FOR A NEW PROGRAMMER DEVICE. THE DEVICE, AS MODIFIED, WILL BEMARKETED UNDER THE TRADE NAME PROMETRA PROGRAMMABLE INFUSION PUMP SYSTEM AND IS INDICATED FOR INTRATHECAL INFUSION OF INFUMORPH (PRESERVATIVE-FREE MORPHINE SULFATE) OR PRESERVATIVE-FREE STERILE 0.9% SALINE SOLUTION (SODIUM CHLORIDE INJECTION, USP).
Source documents
Other decisions for Infusyn Therapeutics, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Prometra Programmable Infusion Pump SystemPMA supplement
P080012-S068 · Decided Jan 12, 2022 · 433 days after receipt · Panel Track
Device type: Pump, infusion, implanted, programmable (LKK) · Hospital Medicine & Nursing
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.